The 20 Best PIK3CA-Related Overgrowth Spectrum Doctors Near Me in Chestnut Hill, MA

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is rated as an Elite provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Triple-Negative Breast Cancer. Dr. Tolaney is board certified in Medical Oncology.

Dr. Sammons is a medical oncologist specializing in the care of patients with all stages of breast cancer. Her research focuses upon improving the outcomes of people living with metastatic breast cancer. She has led multiple clinical trials which have led to new treatment options for patients with metastatic breast cancer. She also has expertise in the treatment of brain metastases. Dr. Sammons received her MD from Sidney Kimmel Medical College in Philadelphia, PA in 2012. She completed her residency in internal medicine at University of Maryland and went on to complete fellowship in medical oncology and hematology at Duke University. In 2018, she joined the staff of Duke Cancer Institute and ultimately served as Associate Director of Breast Cancer Research. She joined Brigham and Women's and Dana-Farber in 2022, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. She serves as Associate Director of the Metastatic Breast Cancer Program. Dr. Sammons is rated as a Distinguished provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Paget Disease of the Breast. Dr. Sammons is board certified in Internal Medicine and Medical Oncology.

Aditya Bardia is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Bardia is rated as an Elite provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Triple-Negative Breast Cancer, Agranulocytosis, and Tissue Biopsy.

Jeffrey Meyerhardt is an Oncologist practicing medicine in Chestnut Hill, Massachusetts. Dr. Meyerhardt is rated as a Distinguished provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, PIK3CA-Related Overgrowth Spectrum, Pancreatic Cancer, and Pancreaticoduodenectomy. Dr. Meyerhardt is board certified in Medical Oncology.

Dejan Juric is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Juric is rated as an Elite provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses PIK3CA-Related Overgrowth Spectrum, Breast Cancer, HER2 Negative Breast Cancer, Tissue Biopsy, and Lithotripsy.

Dr. Mayer received her medical degree from Harvard Medical School, completed her residency in Internal Medicine at Brigham and Women's Hospital, and her fellowship in Medical Oncology at the Dana-Farber Cancer Institute. She also obtained a Masters in Public Health from the Harvard School of Public Health. She joined the staff of Dana-Farber and Brigham and Women's Hospital in 2006, where she serves as Director of Breast Cancer Clinical Research. She is a breast cancer medical oncologist and clinical investigator leading research studies focused on novel therapies for the treatment of breast cancer. Dr. Mayer is rated as an Advanced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Mayer is board certified in Medical Oncology.

Dr. Lynce received her medical degree from the Universidade Nova de Lisboa, Portugal in 2004. She completed her residency in Internal Medicine and fellowship in Hematology and Medical Oncology at MedStar Washington Hospital Center/MedStar Georgetown University Hospital in Washington, DC. She was faculty at MedStar Georgetown University Hospital from 2015 to 2020 where she served as the institutional PI for Alliance and the co-PI for the National Capital Area (NCA) Minority/Underserved NCORP. In 2020, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. Her research focuses on inflammatory breast cancer, triple-negative breast cancer, BRCA-associated breast cancers and novel therapies in the treatment of breast cancer. Dr. Lynce is rated as an Advanced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Inflammatory Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, Angiosarcoma, and Salpingo-Oophorectomy. Dr. Lynce is board certified in Medical Oncology.

Dr. Metzger received his MD from Federal University of Minas Gerais in 2003 and completed training in Internal Medicine and Medical Oncology in 2008. Following his formal training, he spent three years at the Institute Jules Bordet in Brussels where he completed a research fellowship and initiated a career dedicated to understanding the biological features of the second most common histological subtype of breast cancer - invasive lobular carcinoma. Since joining the Breast Oncology Program at Dana-Farber Cancer Institute in 2012, he has established an active clinical practice and developed research efforts focused on identifying better treatment strategies for patients diagnosed with breast cancer. He is involved in designing and leading national and international clinical trials with a strong translational component. In addition to his physician and clinical investigator roles, Dr. Metzger holds an Executive Officer position at the Alliance for Clinical Trials in Oncology. Dr. Metzger is rated as an Advanced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and HER-2 Positive Breast Cancer.

Nolan Priedigkeit, MD, PhD is a medical oncologist at Dana-Farber Cancer Institute (DFCI) and Instructor of Medicine at Harvard Medical School. Clinically, he specializes in breast cancer and his research aims to merge computational and genomic sciences with technology development to make an impact on how we understand and treat metastatic disease. He received dual MD/PhD degrees from the University of Pittsburgh-Carnegie Mellon University Medical Scientist Training Program where his thesis applied translational genomics to discover novel drug targets in advanced breast cancers. He completed an internal medicine residency at Brigham & Women’s Hospital, a medical oncology fellowship at Dana-Farber/Mass General Brigham, and currently leads multidisciplinary research projects at the Broad Institute of MIT & Harvard focused exclusively on breast cancer. He has been supported by awards from the National Cancer Institute, American Association for Cancer Research, Conquer Cancer Foundation of ASCO, Lubin Family Foundation, and the Susan G. Komen Foundation. He values patient-centered care with a focus on open and transparent communication, generous sharing of research data and ideas, as well as mentorship of trainees in both science and medicine. Dr. Priedigkeit is rated as an Advanced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Metastatic Brain Tumor. Dr. Priedigkeit is board certified in Internal Medicine.

Dr. Lin is a medical oncologist specializing in the care of patients with all stages of breast cancer. Her research focuses upon improving the outcomes of people living with metastatic breast cancer, including a particular focus on the challenge of breast cancer brain metastases. She has led multiple clinical trials which have led to new treatment options for patients with breast cancer that has metastasized to the brain. Dr. Lin received her MD from Harvard Medical School in 1999. She completed her residency in internal medicine at Brigham and Women's Hospital and went on to complete fellowships in medical oncology and hematology at Dana-Farber. In 2005, she joined the staff of Brigham and Women's and Dana-Farber, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. Dr. Lin is rated as an Advanced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Brain Tumor, and Inflammatory Breast Cancer. Dr. Lin is board certified in Medical Oncology.

Gerburg Wulf is an Internal Medicine provider practicing medicine in Boston, Massachusetts. Dr. Wulf is rated as an Advanced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Triple-Negative Breast Cancer, and Hormone Replacement Therapy (HRT). Dr. Wulf is board certified in American Board Of Internal Medicine.

Robert Mayer is an Oncologist and a Hematologist practicing medicine in Chestnut Hill, Massachusetts. Dr. Mayer is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Fibrolamellar Carcinoma, Lynch Syndrome, and Agranulocytosis. Dr. Mayer is board certified in Hematology, Internal Medicine, and Medical Oncology.

Nicole Leboeuf is a Dermatologist practicing medicine in Chestnut Hill, Massachusetts. Dr. Leboeuf is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, and Lymphomatoid Papulosis. Dr. Leboeuf is board certified in Dermatology.

Dr. Mossanen is a graduate of the University of California, Los Angeles (UCLA) in Los Angeles, CA and received his medical degree from the David Geffen School of Medicine at UCLA. He also holds a Master of Public Health from the Harvard T.H. Chan School of Public Health in Boston, MA. Dr. Mossanen completed a residency in Urology from the University of Washington in Seattle, WA followed by a fellowship in Urologic Oncology in the Combined Harvard Urologic Oncology Fellowship at Massachusetts General Hospital and Brigham and Women’s Hospital. Dr. Mossanen has been board certified by the American Board of Urology since 2020.His research and clinical interests include: bladder cancer, kidney cancer, kidney masses/cysts, laparoscopic surgery, penile cancer, prostate cancer, robotic surgery, testicular cancer. Dr. Mossanen is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Penile Cancer, Cystectomy, and Nephrectomy. Dr. Mossanen is board certified in Urology.

Steven Tobochnik is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Tobochnik is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Seizures, Epilepsy, Generalized Tonic-Clonic Seizure, and Absence Seizure. Dr. Tobochnik is board certified in Neurology and Epilepsy.

Jong Woo Lee, MD, PhD, directs the Brigham Critical Care Monitoring Program and is the Clinical Director of the Epilepsy Division. He graduated from Harvard College and obtained his medical and doctorate degrees at McGill University and the Montreal Neurological Institute before completing the Partners Neurology Residency and Clinical Neurophysiology Fellowship at BWH. Dr. Lee’s areas of clinical expertise and research interests include critical care EEG, status epilepticus, cardiac arrest prognostication, brain tumor associated seizures, sudden unexpected death in epilepsy, and the medical management of epilepsy. Dr. Lee is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Seizures, Generalized Tonic-Clonic Seizure, Epilepsy, Gastrostomy, and Carotid Artery Surgery. Dr. Lee is board certified in Neurology, Epilepsy, and Clinical Neurophysiology.

Dr. Michael N. Singh is a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH) and an instructor in pediatrics at Harvard Medical School.Dr. Singh received his medical degree from Loma Linda University School of Medicine. He completed a combined residency in medicine/pediatrics at Medical College of Ohio Hospital (now The University of Toledo Medical Center). Dr. Singh then completed a cardiology fellowship at Baystate Medical Center and fellowships in adult congenital heart disease, congenital echocardiography, Marfan syndrome/related connective tissue disorders, and pulmonary hypertension at BWH and Boston Children's Hospital. He is board certified in internal medicine, pediatrics and cardiovascular disease.Dr. Singh’s clinical interests include congenital heart disease, connective tissue disorder and Marfan syndrome. The author of 11 peer-reviewed publications, his research focuses on Marfan syndrome, adults with congenital heart disease and aortic valve dysfunction. Dr. Singh is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 120 other conditions, according to our data. His clinical expertise encompasses Marfan Syndrome, Bicuspid Aortic Valve, Congenital Heart Disease (CHD), and Truncus Arteriosus. Dr. Singh is board certified in Adult Congenital Heart Disease, Cardiovascular Disease, Internal Medicine, and Pediatrics.

Dr. Michael J. Landzberg is the organizing founder and director of the Boston Adult Congenital Heart and Pulmonary Hypertension Group (BACH) at Brigham and Women’s Hospital (BWH). A cardiovascular medicine specialist, he is also an associate professor of medicine at Harvard Medical School (HMS).Dr. Landzberg received his medical degree from HMS. He completed a residency in internal medicine at Columbia-Presbyterian Medical Center and a fellowship in cardiovascular disease at BWH. Dr. Landzberg is board certified in internal medicine.Dr. Landzberg’s clinical interests include adult congenital heart disease and pulmonary hypertension. The author of more than 140 peer-reviewed publications, Dr. Landzberg’s research focuses on the management of congenital heart disease. Dr. Landzberg is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 41 other conditions, according to our data. His clinical expertise encompasses Congenital Heart Disease (CHD), Tetralogy of Fallot, Eisenmenger Syndrome, Heart Transplant, and Patent Foramen Ovale Repair. Dr. Landzberg is board certified in Internal Medicine.

Dr. Anne Marie Valente is the co-director of the Pregnancy and Cardiovascular Disease Program at Brigham and Women’s Hospital and outpatient director of the Boston Adult Congenital Heart Disease & Pulmonary Hypertension Program. A cardiovascular medicine and adult congenital heart disease specialist, she is also an associate professor of medicine and pediatrics at Harvard Medical School. Dr. Valente is the director of the Adult Congenital Heart Disease and Pulmonary Hypertension Senior Fellowship Program at Harvard Medical School.She received her medical degree from University of Vermont College of Medicine. She completed a combined internal medicine/pediatrics residency, as well as pediatric cardiology, adult cardiovascular disease and cardiovascular magnetic resonance imaging fellowships at Duke University Medical Center. Dr. Valente is board certified in internal medicine, pediatrics, cardiovascular disease and pediatric cardiology.Dr. Valente’s clinical and research interests focus on adult congenital heart disease. Her current research examines heart failure complications in patients with repaired tetralogy of Fallot, a congenital heart defect. She has authored over 50 peer-reviewed publications, as well as numerous chapters and reviews about congenital heart disease imaging and the care of women with heart disease during pregnancy. She has received institutional recognition with the Lerner Research Award and the Watkins Discovery Award as well as research funding from the American Heart Association, the Children’s Miracle Network and the National Heart, Lung and Blood Institute.**The BACH program has been training clinicians in the care of adults with congenital heart disease for several decades.  For more information about the Adult Congenital Heart Disease and Pulmonary Hypertension Senior Fellowship Program at Harvard Medical School, please visit the program website.**The BACH program is closely integrated in the Pregnancy and Cardiovascular Disease Program.  This program involves a multi-disciplinary team dedicated to caring for women with heart disease during pregnancy. More information may be found here. Dr. Valente is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 44 other conditions, according to our data. Her clinical expertise encompasses Tetralogy of Fallot, Congenital Heart Disease (CHD), Transposition of the Great Arteries, Cardiac Ablation, and Heart Transplant. Dr. Valente is board certified in Adult Congenital Heart Disease, Cardiovascular Disease, Internal Medicine, Pediatric Cardiology, and Pediatrics.

Patrick Wen is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Wen is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Wen is board certified in Neurology and Neuro-Oncology.